Membership
The coronavirus disease 2019 (COVID-19) pandemic has highlighted the critical importance of global collaboration and equitable access to life-saving vaccines. Despite significant progress, there is an urgent need to expand vaccine production capacities, especially in emerging markets.
By pooling our resources and expertise, we can make a substantial impact on global health and help ensure that vaccines reach those who need them most.
Membership shall be available to entities interested in furthering the objectives of the network.
Companies that wish to become member should:
- Be active in manufacturing of biopharmaceuticals
- Be active in R&D and/or clinical development in LMICs
- Have it's main office in an LMIC in case of public ownership
- Hold majority of the shares by an entity having it's main office in an LMIC in case of private ownership.
